Commissioner McClellan Will Monitor Staff Morale; CBER’s Siegel Departs
This article was originally published in The Gray Sheet
Executive Summary
CBER Office of Therapeutics Review & Research Director Jay Siegel, MD, is the first high-level departure from the agency since the announcement of the CBER/CDER reorganization
You may also be interested in...
CBER Director Zoon Leaving FDA, Will Assume Position At NCI In January
Center for Biologics Evaluation & Research Director Kathryn Zoon's January departure coincides with the establishment of the FDA office of combination products under MDUFMA
CBER Director Zoon Leaving FDA, Will Assume Position At NCI In January
Center for Biologics Evaluation & Research Director Kathryn Zoon's January departure coincides with the establishment of the FDA office of combination products under MDUFMA
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
FDA's five-center structure does not need consolidation beyond the agency's plan to shift biological therapeutic reviews from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research, Acting Commissioner Lester Crawford said